Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The c… Read more
Genome & Company (314130) - Total Assets
Latest total assets as of September 2025: ₩136.75 Billion KRW
Based on the latest financial reports, Genome & Company (314130) holds total assets worth ₩136.75 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genome & Company - Total Assets Trend (2021–2024)
This chart illustrates how Genome & Company’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genome & Company - Asset Composition Analysis
Current Asset Composition (December 2024)
Genome & Company's total assets of ₩136.75 Billion consist of 62.4% current assets and 37.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩65.55 Billion | 44.5% |
| Accounts Receivable | ₩3.74 Billion | 2.5% |
| Inventory | ₩5.77 Billion | 3.9% |
| Property, Plant & Equipment | ₩27.87 Billion | 18.9% |
| Intangible Assets | ₩8.26 Billion | 5.6% |
| Goodwill | ₩14.13 Billion | 9.6% |
Asset Composition Trend (2021–2024)
This chart illustrates how Genome & Company's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genome & Company's current assets represent 62.4% of total assets in 2024, an increase from 59.6% in 2021.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2024, up from 26.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, a decrease from 24.0% in 2021.
- Asset Diversification: The largest asset category is cash and equivalents at 44.5% of total assets.
Genome & Company Competitors by Total Assets
Key competitors of Genome & Company based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Genome & Company - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genome & Company generates 0.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genome & Company is currently not profitable relative to its asset base.
Genome & Company - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 3.02 | 3.02 |
| Quick Ratio | 1.76 | 2.83 | 2.83 |
| Cash Ratio | 0.00 | 1.96 | 1.96 |
| Working Capital | ₩31.02 Billion | ₩ 59.33 Billion | ₩ 59.33 Billion |
Genome & Company - Advanced Valuation Insights
This section examines the relationship between Genome & Company's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.70 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -9.1% |
| Total Assets | ₩147.33 Billion |
| Market Capitalization | $126.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genome & Company's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genome & Company's assets decreased by 9.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genome & Company (2021–2024)
The table below shows the annual total assets of Genome & Company from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩147.33 Billion | -9.09% |
| 2023-12-31 | ₩162.06 Billion | -6.32% |
| 2022-12-31 | ₩173.00 Billion | +26.08% |
| 2021-12-31 | ₩137.22 Billion | -- |